Latest & greatest articles for propranolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for propranolol

1. Propranolol generally safe in treating childhood haemangioma birthmarks

Propranolol generally safe in treating childhood haemangioma birthmarks Signal - Propranolol generally safe in treating childhood haemangioma birthmarks Dissemination Centre Discover Portal NIHR DC Discover Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events. The most common (...) adverse events included coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used, UK preparations

NIHR Dissemination Centre2018

2. Propranolol

Propranolol Top results for propranolol - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for propranolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator

Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator 29699616 2018 04 27 1558-3597 71 17 2018 May 01 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. 1897-1906 S0735-1097(18)33497-1 10.1016/j.jacc.2018.02.056 Electrical storm (ES), characterized by unrelenting recurrences of ventricular (...) arrhythmias, is observed in approximately 30% of patients with implantable cardioverter-defibrillators (ICDs) and is associated with high mortality rates. Sympathetic blockade with β-blockers, usually in combination with intravenous (IV) amiodarone, have proved highly effective in the suppression of ES. In this study, we compared the efficacy of a nonselective β-blocker (propranolol) versus a β 1 -selective blocker (metoprolol) in the management of ES. Between 2011 and 2016, 60 ICD patients (45 men, mean

EvidenceUpdates2018

4. Propranolol generally safe in treating childhood haemangioma birthmarks

Propranolol generally safe in treating childhood haemangioma birthmarks NIHR DC | Signal - Propranolol generally safe in treating childhood haemangioma birthmarks Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events (...) . The most common adverse events included coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used

NIHR Dissemination Centre2018

5. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial

Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial 28970291 2017 10 03 2017 10 03 1468-3288 2017 Sep 28 Gut Gut Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. gutjnl-2017-314634 10.1136/gutjnl-2017-314634 Limited data (...) are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal rebleeding among patients with cirrhosis and PVT. Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24

EvidenceUpdates2017

6. WITHDRAWN: Propranolol for migraine prophylaxis.

WITHDRAWN: Propranolol for migraine prophylaxis. BACKGROUND: Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis. OBJECTIVES: We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine. SEARCH METHODS: Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register (...) of Controlled Trials (Issue 2, 2003), and by screening bibliographies of reviews and identified articles. SELECTION CRITERIA: We included randomised and quasi-randomised clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers. DATA COLLECTION AND ANALYSIS: Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two

Cochrane2017

7. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review 27688361 2016 09 30 2016 12 12 1098-4275 138 4 2016 Oct Pediatrics Pediatrics Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. e20160353 Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this review were to evaluate the safety profile of oral propranolol (...) in the treatment of IH. We searched Embase and Medline databases (2007-July 2014) and unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric formulation of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected studies included ≥10 patients treated with oral propranolol for IH and that either reported ≥1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized and extracted study design, demographic characteristics, IH characteristics

EvidenceUpdates2016

8. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis

A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis 27575713 2016 08 30 2017 02 20 1572-0241 111 11 2016 Nov The American journal of gastroenterology Am. J. Gastroenterol. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. 1582-1590 10.1038/ajg.2016.327 Propranolol has been used (...) as prophylaxis for variceal bleeding in patients with cirrhosis. More recent data suggest that carvedilol may be more effective for reducing the hepatic venous pressure gradient (HVPG) than propranolol. The primary aim of this study was to evaluate the hemodynamic response to carvedilol compared with propranolol. A total of 110 patients with a baseline HVPG value >12 mm Hg were allocated randomly to receive either carvedilol or propranolol. The HVPG measurement was repeated after 6 weeks of daily medication

EvidenceUpdates2016

9. Propranolol (Hemangiol): the drug of first choice for severe infantile haemangiomas

Propranolol (Hemangiol): the drug of first choice for severe infantile haemangiomas Prescrire IN ENGLISH - Spotlight ''Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas '', 1 July 2015 {1} {1} {1} | | > > > Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |    (...) |   |  Spotlight Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas FEATURED REVIEW Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life. When an infant requires medical treatment for haemangioma, oral propranolol is the drug of first choice. Full review (3 pages) available for download by subscribers. Abstract Haemangiomas are benign vascular tumours that generally arise in the skin during the first days

Prescrire2015

10. A randomized, controlled trial of oral propranolol in infantile hemangioma.

A randomized, controlled trial of oral propranolol in infantile hemangioma. BACKGROUND: Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited. METHODS: We performed a multicenter, randomized, double-blind, adaptive, phase 2-3 trial assessing the efficacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age with proliferating infantile hemangioma requiring (...) systemic therapy. Infants were randomly assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for 3 or 6 months). A preplanned interim analysis was conducted to identify the regimen to study for the final efficacy analysis. The primary end point was success (complete or nearly complete resolution of the target hemangioma) or failure of trial treatment at week 24, as assessed by independent, centralized, blinded evaluations

NEJM2015

11. [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)]

[Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Propranolol – Nutzenbewertung gemass Section 35a SGB V [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Propranolol – Nutzenbewertung gemass Section 35a SGB V [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Propranolol – Nutzenbewertung gemass Section 35a SGB V. [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 260. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Childs; Hemangioma; Infant

Health Technology Assessment (HTA) Database.2015

13. Propranolol

Propranolol USE OF PROPRANOLOL IN PREGNANCY 0344 892 0909 USE OF PROPRANOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Propranolol is a non-selective beta-adrenoceptor blocking drug (...) propranolol exposure and women should be made aware of this lack of data. Studies of beta-blockers as a class have not, to date, provided conclusive evidence that use during pregnancy is associated with an increased risk of fetal structural malformations. Although some studies have suggested a possible increased risk of congenital heart defects, this has also been observed with other antihypertensive therapies and may therefore be non-drug-specific or linked to the underlying maternal condition. A meta

UK Teratology Information Service2014

15. A randomized controlled trial of propranolol for infantile hemangiomas

A randomized controlled trial of propranolol for infantile hemangiomas 21788220 2011 08 02 2011 10 13 2013 11 21 1098-4275 128 2 2011 Aug Pediatrics Pediatrics A randomized controlled trial of propranolol for infantile hemangiomas. e259-66 10.1542/peds.2010-0029 Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation. Forty children between the ages of 9 weeks and 5 years with facial IHs or IHs (...) in sites with the potential for disfigurement were randomly assigned to receive propranolol or placebo oral solution 2 mg/kg per day divided 3 times daily for 6 months. Baseline electrocardiogram, echocardiogram, and laboratory evaluations were performed. Monitoring of heart rate, blood pressure, and blood glucose was performed at each visit. Children younger than 6 months were admitted to the hospital for monitoring after their first dose at weeks 1 and 2. Efficacy was assessed by performing blinded

EvidenceUpdates2011

16. Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices

Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Jutabha R, Jensen D M, Martin P, Savides T, Han S H, Gornbein J Record Status (...) . Of these, 197 were excluded from randomisation and 62 were randomised. Randomisation assigned 31 to prophylactic oesophageal variceal ligation and 31 to prophylactic propranolol. Study design The study was an RCT that was carried out in three centres (Los Angeles Medical Centre, San Diego Medical Centre and Veterans Administration Los Angeles HealthCare System). A separate randomisation schedule was provided for each centre in permuted blocks of 4. The follow-up period was up to 2 years. Treatment

NHS Economic Evaluation Database.2005

17. Do pizotifen or propranolol reduce the frequency of migraine headache?

Do pizotifen or propranolol reduce the frequency of migraine headache? BestBets: Do pizotifen or propranolol reduce the frequency of migraine headache Do pizotifen or propranolol reduce the frequency of migraine headache Report By: Nick Barnes - Specialist Registrar Search checked by Guy Millman - Specialist Registrar Institution: John Radcliffe Hospital, Oxford, UK and Royal Manchester Children's Hospital, Manchester, UK respectively Date Submitted: 19th March 2004 Date Completed: 13th July (...) 2004 Last Modified: 13th July 2004 Status: Green (complete) Three Part Question In [an adolescent with frequent migrainous headache] does the [prescription of pizotifen or propranolol] [reduce the frequency and/or the severity of migraine attacks]? Clinical Scenario Once again you find yourself in a busy general paediatric clinic faced with a 14-year-old girl suffering from recurrent headaches for the last 9 months. The history would suggest frequent attacks of a migrainous nature without aura

BestBETS2004

18. Propranolol for migraine prophylaxis.

Propranolol for migraine prophylaxis. BACKGROUND: Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis. OBJECTIVES: We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine. SEARCH STRATEGY: Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register of Controlled (...) Trials (Issue 2, 2003), and by screening bibliographies of reviews and identified articles. SELECTION CRITERIA: We included randomised and quasi-randomised clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers. DATA COLLECTION AND ANALYSIS: Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two

Cochrane2004

19. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding.

Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. 10099140 1999 04 01 1999 04 01 2013 11 21 0028-4793 340 13 1999 Apr 01 The New England journal of medicine N. Engl. J. Med. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. 988-93 We compared propranolol therapy and endoscopic ligation for the primary prevention of bleeding from esophageal varices. This prospective, controlled trial included (...) consecutive eligible patients who had large varices (>5 mm in diameter) that were at high risk for bleeding. The patients were assigned to either propranolol therapy, at a dose sufficient to decrease the base-line heart rate by 25 percent, or variceal ligation, to be performed weekly until the varices were obliterated or so reduced in size that it was not possible to continue treatment. Of the 89 patients, 82 of whom had cirrhosis of the liver, 44 received propranolol and 45 underwent variceal ligation

NEJM1999

20. Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis

Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T Authors' objectives To assess the efficacy of the beta-blocker propranolol (...) (RCTs). In addition, the studies had to be published as an abstract or article; include patients with cirrhosis and oesophageal varices, patients enrolled after initial rebleeding from oesophageal varices, and patients in whom bleeding was not treated with sclerotherapy; a comparison of propranolol with endoscopic sclerotherapy; have a mean follow-up of more than 11 months; and have at least one of the previously mentioned end points. Specific interventions included in the review Propranolol

DARE.1997